elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Docetaxel
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Docetaxel
RIS
0.003
(Research Intensity Score)
Papers
458
Top papers
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
2021 · 1181 citations
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
2024 · 170 citations
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
2024 · 124 citations
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
2022 · 274 citations
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
2019 · 2619 citations
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
2025 · 49 citations
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial
2025 · 52 citations
Sacituzumab tirumotecan versus docetaxel for previously treated EGFR -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial
2025 · 42 citations
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
2018 · 1703 citations
Newest papers
Data from Clonal Hematopoiesis after <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
2026 · 1 citations
Aptamer-functionalized 3D gold nanodendrite platform for electrochemical detection of circulating tumor cells in breast cancer
2026 · 3 citations
Canadian Cancer Trials Group (CCTG) study PR21 (PLUDO): Results of crossover treatment from a randomized trial of 177 Lu-PSMA-617 (LuP) vs docetaxel (DOC) in patients with metastatic castration-resistant prostate cancer (mCRPC).
2026 · 1 citations
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
2026 · 1 citations
Diagnosis and treatment of metastatic prostate cancer in low- and middle-income countries: challenges, adaptive strategies, and lessons from sub-Saharan Africa
2026
TPD54 contributes to docetaxel resistance through modulation of P‑glycoprotein localization and activity in oral squamous cell carcinoma cells
2026
Comparator-dependent evidence for earlier PSMA-targeted radioligand therapy in prostate cancer: a systematic review and meta-analysis of randomized trials
2026
Evolving Systemic Therapy for Prostate Cancer: Pivotal Clinical Trials, Biomarker-Driven Combinations, and Practical Sequencing in the ARSI–PARP–Radioligand Era
2026 · 1 citations
Sequential therapy with radium-223 chloride and 177Lu-PSMA in patients with metastatic castration-resistant prostate cancer
2026
Browse all papers →
Docetaxel's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Docetaxel's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link